CG Oncology (CGON) EBIT Margin (2023 - 2025)
Historic EBIT Margin for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 3068.97%.
- CG Oncology's EBIT Margin rose 627333600.0% to 3068.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 8285.33%, marking a year-over-year increase of 57456700.0%. This contributed to the annual value of 10067.25% for FY2024, which is 171136300.0% up from last year.
- Per CG Oncology's latest filing, its EBIT Margin stood at 3068.97% for Q3 2025, which was up 627333600.0% from 81161.54% recorded in Q1 2025.
- CG Oncology's EBIT Margin's 5-year high stood at 3068.97% during Q3 2025, with a 5-year trough of 1935500.0% in Q4 2023.
- Moreover, its 3-year median value for EBIT Margin was 23290.99% (2024), whereas its average is 253606.61%.
- In the last 5 years, CG Oncology's EBIT Margin skyrocketed by 2000000000bps in 2024 and then crashed by -769140900bps in 2025.
- Quarter analysis of 3 years shows CG Oncology's EBIT Margin stood at 1935500.0% in 2023, then skyrocketed by 100bps to 8344.08% in 2024, then skyrocketed by 63bps to 3068.97% in 2025.
- Its EBIT Margin stands at 3068.97% for Q3 2025, versus 81161.54% for Q1 2025 and 8344.08% for Q4 2024.